CNS Depressants

FDA: Opioid Addiction Medication Should Not Be Withheld While Taking CNS Depressants

FDA: Opioid Addiction Medication Should Not Be Withheld While Taking CNS Depressants

By

A review of several published studies showed that the evidence did not support dose limitations or arbitrary caps of buprenorphine or methadone as a strategy to address benzodiazepine or other CNS depressant use in MAT-treated patients.

FDA's Strategies for Managing Patients Taking CNS Depressants and Opioids

FDA's Strategies for Managing Patients Taking CNS Depressants and Opioids

By

The FDA has recently issued a report advising against the use of buprenorphine and methadone medications in patients taking benzodiazepines and/or other central nervous system depressants.

Sign Up for Free e-Newsletters